<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/59C40697-7AB2-4E2B-B2B6-202A835DC125"><gtr:id>59C40697-7AB2-4E2B-B2B6-202A835DC125</gtr:id><gtr:firstName>Claire</gtr:firstName><gtr:surname>Kelly</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/54BFDEDC-CB9B-4DED-9910-276995C85774"><gtr:id>54BFDEDC-CB9B-4DED-9910-276995C85774</gtr:id><gtr:firstName>Jim</gtr:firstName><gtr:surname>Cassidy</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/117359C3-F606-49D8-88F0-858131A49721"><gtr:id>117359C3-F606-49D8-88F0-858131A49721</gtr:id><gtr:firstName>Timothy</gtr:firstName><gtr:surname>Iveson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/333FB934-34B3-42EA-BFC7-A65D2CBB0F12"><gtr:id>333FB934-34B3-42EA-BFC7-A65D2CBB0F12</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Briggs</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8273EDE9-E177-43CA-AB9E-8387418B2917"><gtr:id>8273EDE9-E177-43CA-AB9E-8387418B2917</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Kerr</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/72046F29-E39F-4826-85D9-F364418330B4"><gtr:id>72046F29-E39F-4826-85D9-F364418330B4</gtr:id><gtr:firstName>Jim</gtr:firstName><gtr:surname>Paul</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601705"><gtr:id>5C125A73-8FEB-488A-80BD-1CBE2D6150CE</gtr:id><gtr:title>SCOT- Short Course Oncology Therapy - A study of Adjuvant Chemotherapy in colorectal ca by the CACTUS &amp;amp; QUASAR 3 Groups.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601705</gtr:grantReference><gtr:abstractText>Bowel cancer is a common disease. Most patients will have an operation to remove the cancer. Unfortunately the cancer will come back in 1 out of 2 patients. There is evidence to suggest that a 6-month course of chemotherapy can reduce the chance of the cancer coming back by killing the cancer cells that may have been left behind after surgery. 
In the past, patients have received 6 months of chemotherapy treatment. Chemotherapy has side effects and many of these side effects get worse as the treatment goes on. There is some evidence that 3 months treatment provides the same benefit as 6 months, but this has never been directly compared. The aim of this study is to find out if 3 months of chemotherapy is just as effective as 6 months, with fewer side effects. 
This study will enrol over 9000 patients from all over the UK. Half of the patients will receive chemotherapy for 6 months and half will receive chemotherapy for 3 months. We will be following these patients closely for many years to see if the effect of the two treatments is the same. We will also be looking at the side effects of the treatment and how this affects quality of life, and whether the cost of treatment is affected. 
If this study does show that 3 months of treatment is as effective as 6 months it will lead to a major change in the way bowel cancer patients are treated in future. Treatment will be shorter with fewer side effects and will be more cost effective. This will be of enormous benefit to the individual patient, healthcare providers and society at large.</gtr:abstractText><gtr:technicalSummary>Colorectal cancer is the second leading cause of cancer mortality in the UK. Following a complete surgical resection, patients face a 40-50% chance of disease relapse. Currently the standard adjuvant chemotherapy is six months of 5-flourouracil?based chemotherapy. Newer chemotherapy agents have increased the toxicity profile of chemotherapy in this disease.

The primary research objective of this trial is to ascertain whether three months of adjuvant treatment for colorectal cancer is as efficacious as six months of treatment. The secondary objectives are to assess the toxicity, economic and quality of life implications of shortening therapy. There is currently very limited evidence for reducing the duration of treatment, and therefore toxicity and cost.

This trial will be an open, randomised, controlled, multi-centre non-inferiority clinical trial. The outcomes measured will be disease?free survival, overall survival, cost-effectiveness, toxicity and quality of life.

The study incorporates a nested methodological sub-study addressing the question of the best time to randomise in non-inferiority studies aimed at reducing a standard treatment duration (before treatment starts or at the early stopping point), This substudy will run for the first 12 months of recruitment and also act as an internal pilot for the feasibility of the study as a whole.

It is proposed that a number of translational laboratory studies will run in parallel with this clinical trial.

Should this trial prove positive, it is likely that clinical practice worldwide will be significantly altered in line with the results. The potential benefit to patients, healthcare providers and society at large in terms of reduced toxicity and cost are far reaching.</gtr:technicalSummary><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2707635</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>25500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>transSCOT - sample collection for translational studies in colorectal cancer</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C6716/A13941</gtr:fundingRef><gtr:id>32945B9F-4F1F-4895-8393-C0495D953623</gtr:id><gtr:outcomeId>BsA9N54MMVj</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7B6652D9-D24E-46DD-BF4D-E4B2F2520B0C</gtr:id><gtr:title>Toxicity and quality of life data from SCOT: An international phase III randomized (1: 1) noninferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy.</gtr:title><gtr:parentPublicationTitle>ASCO Annual Meeting Proceedings</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1588d722e51b475ced6324f8d7d4f7e0"><gtr:id>1588d722e51b475ced6324f8d7d4f7e0</gtr:id><gtr:otherNames>Iveson T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>570b982ab5ef54.03712434</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D950490B-012D-4125-B230-11BC61A35A25</gtr:id><gtr:title>Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a16de7ac6d29bef27d7049a16cb511d3"><gtr:id>a16de7ac6d29bef27d7049a16cb511d3</gtr:id><gtr:otherNames>Paul J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>BHZ9BZcR2nK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB291343-1716-4564-8573-BF66023314D3</gtr:id><gtr:title>SCOT: Short Course Oncology Therapy-A comparison of 12 and 24 weeks of adjuvant chemotherapy in colorectal cancer</gtr:title><gtr:parentPublicationTitle>Journal of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd9ee0fc5dfa5e07b71614d18398ec1e"><gtr:id>bd9ee0fc5dfa5e07b71614d18398ec1e</gtr:id><gtr:otherNames>Paul, James</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>TwtVp6M5mef</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A531D534-7AAF-4FFD-84B8-AB5B60C699E2</gtr:id><gtr:title>The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6&amp;nbsp;months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status.</gtr:title><gtr:parentPublicationTitle>Current colorectal cancer reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5975f1e94908c1276aff83ef8ba9edad"><gtr:id>5975f1e94908c1276aff83ef8ba9edad</gtr:id><gtr:otherNames>Andr? T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1556-3790</gtr:issn><gtr:outcomeId>56e196d6366897.51174054</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C34AC55-D9B5-4B4B-904E-18F01E223BD8</gtr:id><gtr:title>Final DFS results of the SCOT study: An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer.</gtr:title><gtr:parentPublicationTitle>JOURNAL OF CLINICAL ONCOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b363bea126bca169603b233c6b05e62a"><gtr:id>b363bea126bca169603b233c6b05e62a</gtr:id><gtr:otherNames>Iveson Timothy</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>5aa6ab5a85ff85.04491591</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D54D27F3-A43F-4316-9937-6AB2C4B98B3D</gtr:id><gtr:title>Updated results of the SCOT study: An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer</gtr:title><gtr:parentPublicationTitle>ANNALS OF ONCOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8c7d9a036bc28e9b1d644b2e9fd7fee"><gtr:id>e8c7d9a036bc28e9b1d644b2e9fd7fee</gtr:id><gtr:otherNames>Iveson T.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>5aa6ab5ac92239.39650364</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601705</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>